Barclays PLC Dynavax Technologies Corp Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Barclays PLC holds 237,415 shares of DVAX stock, worth $2.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

237,415

Previous 290,384 18.24%

Holding current value

$2.26 Million

Previous $3.71 Million 16.94%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$12.39 - $14.4 $656,285 - $762,753	-52,969 Reduced 18.24%	237,415 $3.08 Million
Q4 2024 Feb 13, 2025	SELL	$10.28 - $13.66 $125,292 - $166,488	-12,188 Reduced 4.03%	290,384 $3.71 Million
Q3 2024 Nov 15, 2024	BUY	$10.05 - $11.61 $1.76 Million - $2.03 Million	175,118 Added 137.4%	302,572 $3.37 Million
Q2 2024 Aug 14, 2024	SELL	$10.73 - $12.58 $264,687 - $310,323	-24,668 Reduced 16.22%	127,454 $1.43 Million
Q1 2024 May 15, 2024	SELL	$11.7 - $14.98 $2.93 Million - $3.75 Million	-250,312 Reduced 62.2%	152,122 $1.89 Million
Q4 2023 Feb 15, 2024	BUY	$13.09 - $14.98 $1.63 Million - $1.86 Million	124,268 Added 44.67%	402,434 $5.63 Million
Q3 2023 Nov 07, 2023	BUY	$12.64 - $14.99 $305,331 - $362,098	24,156 Added 9.51%	278,166 $4.11 Million
Q2 2023 Aug 03, 2023	BUY	$9.85 - $13.17 $248,141 - $331,778	25,192 Added 11.01%	254,010 $3.28 Million
Q1 2023 May 04, 2023	SELL	$9.44 - $11.88 $1.42 Million - $1.79 Million	-150,343 Reduced 39.65%	228,818 $2.24 Million
Q4 2022 Feb 13, 2023	SELL	$10.27 - $13.29 $188,351 - $243,738	-18,340 Reduced 4.61%	379,161 $4.03 Million
Q3 2022 Nov 03, 2022	BUY	$9.93 - $17.44 $3.57 Million - $6.27 Million	359,235 Added 938.78%	397,501 $4.15 Million
Q2 2022 Aug 12, 2022	SELL	$7.45 - $12.83 $590,688 - $1.02 Million	-79,287 Reduced 67.45%	38,266 $482,000
Q1 2022 May 16, 2022	SELL	$9.75 - $14.44 $183,699 - $272,064	-18,841 Reduced 13.81%	117,553 $1.28 Million
Q4 2021 Feb 14, 2022	BUY	$13.17 - $20.94 $1.21 Million - $1.92 Million	91,832 Added 206.08%	136,394 $1.92 Million
Q3 2021 Nov 09, 2021	SELL	$9.16 - $19.83 $1.04 Million - $2.25 Million	-113,550 Reduced 71.82%	44,562 $856,000
Q2 2021 Aug 13, 2021	SELL	$7.25 - $10.99 $1.68 Million - $2.54 Million	-231,354 Reduced 59.4%	158,112 $1.56 Million
Q1 2021 May 13, 2021	BUY	$4.57 - $11.18 $1.53 Million - $3.74 Million	334,454 Added 607.97%	389,466 $3.83 Million
Q4 2020 Feb 11, 2021	SELL	$3.73 - $5.6 $3,550 - $5,331	-952 Reduced 1.7%	55,012 $243,000
Q3 2020 Nov 12, 2020	SELL	$4.32 - $11.7 $35,022 - $94,851	-8,107 Reduced 12.65%	55,964 $242,000
Q2 2020 Aug 12, 2020	BUY	$2.94 - $9.1 $5,447 - $16,862	1,853 Added 2.98%	64,071 $568,000
Q1 2020 May 13, 2020	SELL	$2.27 - $6.2 $114,008 - $311,388	-50,224 Reduced 44.67%	62,218 $220,000
Q4 2019 Feb 10, 2020	BUY	$3.46 - $6.93 $152,592 - $305,626	44,102 Added 64.53%	112,442 $644,000
Q3 2019 Nov 14, 2019	BUY	$2.69 - $4.85 $51,661 - $93,144	19,205 Added 39.09%	68,340 $244,000
Q2 2019 Aug 14, 2019	BUY	$3.65 - $7.89 $69,915 - $151,132	19,155 Added 63.89%	49,135 $196,000
Q1 2019 May 15, 2019	BUY	$7.08 - $12.09 $212,258 - $362,458	29,980 New	29,980 $220,000
Q4 2018 Feb 14, 2019	SELL	$8.14 - $13.28 $201,359 - $328,507	-24,737 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$11.85 - $16.0 $142,010 - $191,744	-11,984 Reduced 32.64%	24,737 $307,000
Q2 2018 Aug 14, 2018	SELL	$15.15 - $20.75 $103,959 - $142,386	-6,862 Reduced 15.74%	36,721 $559,000
Q1 2018 May 15, 2018	SELL	$14.65 - $19.9 $614,904 - $835,262	-41,973 Reduced 49.06%	43,583 $865,000
Q4 2017 Feb 14, 2018	SELL	$17.3 - $24.08 $253,081 - $352,266	-14,629 Reduced 14.6%	85,556 $1.6 Million
Q3 2017 Nov 14, 2017	BUY	$15.2 - $21.5 $1.52 Million - $2.15 Million	100,185	100,185 $2.15 Million

Others Institutions Holding DVAX

# of Institutions

312

Shares Held

129M

Call Options Held

493K

Put Options Held

269K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.2B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account